Clinical Trials
6 trialsNCT04997902 2025-12-23
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Kura Oncology, Inc.
Phase 1/2 Completed
NCT02464228 2024-06-26
PTCL
Kura Oncology, Inc.
Phase 2 Completed
NCT00847223 2018-08-23
Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma
Lymphoma Study Association
Phase 2 Terminated
NCT02210858 2018-06-04
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00383474 2015-04-15
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
National Cancer Institute (NCI)
Phase 1 Completed
NCT00354146 2011-02-01
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed